drugset / Trial / NCT02340988
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oritavancin | Other / unclassified | 1200 mg | Intravenous |
| Subject | Warfarin | Small molecule | 25 mg | — |
Indications
No indication recorded.